Czego jeszcze nie wiemy o pantoprazolu? Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
wrz 30, 2015
Słowa kluczowe:
pantoprazol, choroba refluksowa przełyku, nienadżerkowa choroba refluksowa
##plugins.themes.bootstrap3.article.main##
Abstrakt
Pantoprazol, dzięki swojemu profilowi bezpieczeństwa i skuteczności, jest już od pewnego czasu jednym z najskuteczniejszych inhibitorów pompy protonowej. Niemniej jednak w ostatnich latach w nowych badaniach związanych z wpływem pantoprazolu na metabolizm leków wykazano inne możliwości jego zastosowania, np. w przypadku cukrzycy typu II czy też w onkologii – jako leku modyfikującego przebieg metabolizmu innych leków.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Waśko-Czopnik , D. (2015). Czego jeszcze nie wiemy o pantoprazolu? . Medycyna Faktów , 8(3(28), 51-55. Pobrano z https://journalsmededu.pl/index.php/jebm/article/view/2296
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Brunner G., Athmann C., Schneider A.: Long-term, open label trial: safety and efficacy of continuous maintenance treatment with pantoprazole for up to 15 years in severe acid-peptic disease. Aliment. Pharmacol. Ther. 2012; 36: 37-47.
2. Brunner G., Harke U.: Long-term therapy with pantoprazole in patients with peptic ulceration resist to extended high-dose reanitidine treatment. Aliment. Pharmacol. Ther. 1994; 8(supl. 1): 59-64.
3. Genta R.M.: Acid suppression and gastric atrophy: sifting fact from fiction. Gut 2009; 43: S35-38.
4. Dąbrowski A.: Skuteczność i bezpieczeństwo pantoprazolu (Nolpaza) w leczeniu pacjentów z chorobą refluksową przełyku – wyniki badania PAN-STAR. Gastroenterologia Praktyczna 2014; 1: 1-12.
5. Klikenberg-Knol E.C., Nelis F., Dent J. et al.: Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety an influence on gastric mucosa. Gastroenterology 2000; 119: 661-669.
6. Lamberts R., Brunner G., Solcia E.: Effects of very long (up to 10 years) proton pomp blockade on human gastric mucosa. Digestion 2001; 64: 205-213.
7. Kataz P.O., Gerson L.B., Vela M.F.: Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am. J. Gastroenterol. 2013; 108: 308-328.
8. Fass R.: Erosive esophagitis and nonerosive reflux disease (NERD) – comparison of epidemiologic, physiologic and therapeutic characteristics. J. Clin. Gastroenterol. 2007; 41: 131-137.
9. Fass R., Shapiro M., Dekel R. et al.: Systematic review: proton pump inhibitor failure in gastroesophageal reflux disease – where next? Aliment. Pharmacol. Ther. 2005; 22: 79-94.
10. Ji-Xiang Z., Meng-Yao J., Jia S. et al.: Proton pump inhibitor for non-erosive reflux disease: a meta-analysis. World J. Gastroenterol. 2013; 19(45): 8408-8419.
11. Wedemeyer R.S., Blume H.: Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update. Drug Saf. 2014 [doi:10.1007/s40264-014-0144-0].
12. Gerson L.B., Triadafilopoulos G.: Proton pump inhibitors and their drug interactions: an evidence-based approach. Eur. J. Gastroenterol. Hepatol. 2001; 13(5): 611-616.
13. Laine L.: Proton pomp inhibitor co-therapy with clopidogrel: is there GI benefit or cardiovascular harm? Gastroenterology 2011: 140(3): 769-772.
14. Kwok C.S., Loke Y.K.: Meta-analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel Aliment Pharmacol. Ther. 2010; 31(8): 810-823.
15. Duursema L., Muller F.O., Schall R., Middle M.V. et al.: Lack of effect of pantoprazole on the pharmacodynamics and pharmacokinetics of warfarin. Br. J. Clin. Pharmac. 1995; 39: 700-703.
16. Gugler R., Hartmann M., Rudi J. et al.: Lack of pharmacokinetic interaction of pantoprazole with diazepam in man. Br. J. Clin. Pharmacol. 1996; 42: 249-252.
17. Ward R.M., Kearns G.L., Brinda T. et al.: A multicenter, randomized, open-label, pharmacokinetics and safety study of pantoprazole tablets in children and adolescets aged 6 through 16 years with GERD. J. Clin. Pharmacol. 2011; 51(6): 876-887.
18. Monnikes H., Heading R.C., Schmitt H. et al.: Influence of irritable bowel syndrome on treatment outcome in gastroesophageal reflux disease. World J. Gastroenterol. 2011; 21: 17(27): 3235-3231.
19. Inci F., Atmaca M., Ozturk M. et al.: Pantoprazole may improve beta cell function and diabetes mellitus. J. Endocrinol. Invest. 2014; 37(5): 449-454.
20. González-Ortiz M., Martínez-Abundis E., Mercado-Sesma A.R. et al.: Effect of pantoprazole on insulin secretion in drug-naïve patients with type 2 diabetes. Diabetes Res. Clin. Pract. 2015; 108(1): e11.
21. Brana I., Ocana A., Chen E.X. et al.: Phase I trial of pantoprazole in combination with doxorubicin in patients with advanced solid tumors: evaluation of pharmacokinetics of both drugs and tissue penetration of doxorubicin. Invest. New Drugs 2014; 32(6): 1269-1277.
22. Zhang B., Yang Y., Shi X. et al.: Proton pump inhibitor pantoprazole abrogates adriamycin-resistant gastric cancer cell invasiveness via suppression of Akt/GSK-β/β-catenin signaling and epithelial-mesenchymal transition. Cancer Lett. 2015; 28; 356(2 Pt B): 704-712.
23. Shen W., Zou X., Chen M. et al.: Effect of pantoprazole on human gastric adenocarcinoma SGC7901 cells through regulation of phospho LRP6 expression in Wnt/β-catenin signaling. Oncol. Rep. 2013; 30(2): 851-855.
24. Tan Q., Joshua A.M., Saggar J.K.: Effect of pantoprazole to enhance activity of docetaxel against human tumour xenografts by inhibiting autophagy. Br. J. Cancer 2015; 3; 112(5): 832-840.
2. Brunner G., Harke U.: Long-term therapy with pantoprazole in patients with peptic ulceration resist to extended high-dose reanitidine treatment. Aliment. Pharmacol. Ther. 1994; 8(supl. 1): 59-64.
3. Genta R.M.: Acid suppression and gastric atrophy: sifting fact from fiction. Gut 2009; 43: S35-38.
4. Dąbrowski A.: Skuteczność i bezpieczeństwo pantoprazolu (Nolpaza) w leczeniu pacjentów z chorobą refluksową przełyku – wyniki badania PAN-STAR. Gastroenterologia Praktyczna 2014; 1: 1-12.
5. Klikenberg-Knol E.C., Nelis F., Dent J. et al.: Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety an influence on gastric mucosa. Gastroenterology 2000; 119: 661-669.
6. Lamberts R., Brunner G., Solcia E.: Effects of very long (up to 10 years) proton pomp blockade on human gastric mucosa. Digestion 2001; 64: 205-213.
7. Kataz P.O., Gerson L.B., Vela M.F.: Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am. J. Gastroenterol. 2013; 108: 308-328.
8. Fass R.: Erosive esophagitis and nonerosive reflux disease (NERD) – comparison of epidemiologic, physiologic and therapeutic characteristics. J. Clin. Gastroenterol. 2007; 41: 131-137.
9. Fass R., Shapiro M., Dekel R. et al.: Systematic review: proton pump inhibitor failure in gastroesophageal reflux disease – where next? Aliment. Pharmacol. Ther. 2005; 22: 79-94.
10. Ji-Xiang Z., Meng-Yao J., Jia S. et al.: Proton pump inhibitor for non-erosive reflux disease: a meta-analysis. World J. Gastroenterol. 2013; 19(45): 8408-8419.
11. Wedemeyer R.S., Blume H.: Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update. Drug Saf. 2014 [doi:10.1007/s40264-014-0144-0].
12. Gerson L.B., Triadafilopoulos G.: Proton pump inhibitors and their drug interactions: an evidence-based approach. Eur. J. Gastroenterol. Hepatol. 2001; 13(5): 611-616.
13. Laine L.: Proton pomp inhibitor co-therapy with clopidogrel: is there GI benefit or cardiovascular harm? Gastroenterology 2011: 140(3): 769-772.
14. Kwok C.S., Loke Y.K.: Meta-analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel Aliment Pharmacol. Ther. 2010; 31(8): 810-823.
15. Duursema L., Muller F.O., Schall R., Middle M.V. et al.: Lack of effect of pantoprazole on the pharmacodynamics and pharmacokinetics of warfarin. Br. J. Clin. Pharmac. 1995; 39: 700-703.
16. Gugler R., Hartmann M., Rudi J. et al.: Lack of pharmacokinetic interaction of pantoprazole with diazepam in man. Br. J. Clin. Pharmacol. 1996; 42: 249-252.
17. Ward R.M., Kearns G.L., Brinda T. et al.: A multicenter, randomized, open-label, pharmacokinetics and safety study of pantoprazole tablets in children and adolescets aged 6 through 16 years with GERD. J. Clin. Pharmacol. 2011; 51(6): 876-887.
18. Monnikes H., Heading R.C., Schmitt H. et al.: Influence of irritable bowel syndrome on treatment outcome in gastroesophageal reflux disease. World J. Gastroenterol. 2011; 21: 17(27): 3235-3231.
19. Inci F., Atmaca M., Ozturk M. et al.: Pantoprazole may improve beta cell function and diabetes mellitus. J. Endocrinol. Invest. 2014; 37(5): 449-454.
20. González-Ortiz M., Martínez-Abundis E., Mercado-Sesma A.R. et al.: Effect of pantoprazole on insulin secretion in drug-naïve patients with type 2 diabetes. Diabetes Res. Clin. Pract. 2015; 108(1): e11.
21. Brana I., Ocana A., Chen E.X. et al.: Phase I trial of pantoprazole in combination with doxorubicin in patients with advanced solid tumors: evaluation of pharmacokinetics of both drugs and tissue penetration of doxorubicin. Invest. New Drugs 2014; 32(6): 1269-1277.
22. Zhang B., Yang Y., Shi X. et al.: Proton pump inhibitor pantoprazole abrogates adriamycin-resistant gastric cancer cell invasiveness via suppression of Akt/GSK-β/β-catenin signaling and epithelial-mesenchymal transition. Cancer Lett. 2015; 28; 356(2 Pt B): 704-712.
23. Shen W., Zou X., Chen M. et al.: Effect of pantoprazole on human gastric adenocarcinoma SGC7901 cells through regulation of phospho LRP6 expression in Wnt/β-catenin signaling. Oncol. Rep. 2013; 30(2): 851-855.
24. Tan Q., Joshua A.M., Saggar J.K.: Effect of pantoprazole to enhance activity of docetaxel against human tumour xenografts by inhibiting autophagy. Br. J. Cancer 2015; 3; 112(5): 832-840.